Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

Novo Nordisk stock slumped early Monday as the drugmaker was facing a potential hit to revenue from several different ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The best metric is not weight, but a particularly toxic kind of fat.

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Lilly's study showed that more patients treated with Zepbound had reductions in body weight of at least 10%, 15%, 20%, and 25% than those treated with Wegovy, while they also achieved a greater ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...